Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis

Lei Zhang, Wei-Qiang Tan, Qing-Qing Fang, Wan-Yi Zhao, Qi-Ming Zhao, Jie Gao, and Xiao-Wei Wang

1 Department of Orthopaedics, Xiaoshan Hospital of Traditional Chinese Medicine, Hangzhou 311201, China
2 Department of Plastic Surgery, Affiliated Sir Run Run Shaw Hospital to Zhejiang University School of Medicine, Hangzhou 310016, China
3 Department of Plastic Surgery, The First Affiliated Hospital to Zhejiang University School of Medicine, Hangzhou 310003, China
4 Department of Plastic Surgery, Zhejiang Hospital, Hangzhou 310003, China

Correspondence should be addressed to Xiao-Wei Wang; 1256215620@qq.com

Lei Zhang and Wei-Qiang Tan contributed equally to this work.

Received 13 June 2018; Accepted 17 September 2018; Published 6 November 2018

Academic Editor: Arjen F. Nikkels

Copyright © 2018 Lei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Melasma is a highly prevalent, chronic, and pigmented disorder. This systematic review aims to evaluate the efficacy and safety of tranexamic acid (TA) for the treatment of adults with melasma. Methods. We independently searched 3 databases from beginning to 26 April, 2018. The study included 21 eligible trials. Two writers extracted data at the same time independently. Study outcomes were calculated by standardized mean differences (SMD) with 95% confidence intervals (CIs). All statistical analyses were performed using Review Manager Version 5.3 and STATA Version 15.1. Results. The combined results showed that the use of TA was associated with reduced Melasma Area and Severity Index (MASI) and Melanin Index (MI). No significant difference in Erythema Index (EI) was observed with TA treatment. Side effects were minor, with a few cases reporting mild gastrointestinal reaction, oligomenorrhea, hypopigmentation, urticarial rash, and skin irritation xerosis. Conclusion. The meta-analysis suggested that TA treatment appeared to be a promising therapeutic approach for melasma.

1. Introduction

Melasma, also referred to as chloasma, is a common acquired condition of pigmentary disorder marked by irregular hyperpigmented macules or patches and most commonly occurs in females with dark skin types living in areas of intense ultraviolet (UV) light exposure. The prevalence of melasma reported in recent studies ranges from 8.8% to 40% based on ethnic makeup of the population [1, 2]. Many factors are linked with the development of melasma, including UV radiation, pregnancy, hormonal activity, thyroid abnormalities, and medications [3]. Furthermore, there appears to be a genetic predisposition of melasma. All these diverse factors trigger the increased synthesis of melanosomes in melanocytes and increased transfer of melanosomes to keratinocytes [4].

The treatments for melasma are generally aimed at inhibiting the pathways that synthesize melanin and decrease of melanosome transfer from melanocyte to keratinocytes. Because both UV and visible light can induce pigmentation, the therapy usually starts with the protection of UV sun, and topical lightening formulation. Moreover, various subsequent treatments of melasma include hypopigmenting agents, chemical peels, lasers, and dermabrasion [5]. However, melasma is often difficult to treat and can be psychosocially detrimental to many patients [6–9]. Some topical agents, such as hydroquinone, are limited by complications including irritant dermatitis, allergic contact dermatitis, postinflammatory hyperpigmentation, nail bleaching, and exogenous ochronosis [2]. Furthermore, physical treatments such as chemical peels and low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser (QSNY) need multiple
courses over several months. However, the side effects and financial burden of these treatments limit their clinical application [10].

Tranexamic acid (trans-4-(Aminomethyl)cyclohexane-carboxylic acid, TA), a plasmin inhibitor, is used as a hemostatic agent to treat abnormal fibrinolysis to prevent excessive bleeding. It is a synthetic derivative of the amino acid lysine and exerts its effect by competitively inhibiting the activation of plasminogen activator (PA) through reversible interactions with its lysine-binding sites, thus inhibiting PA from converting plasminogen to plasmin [32]. TA is a relatively new drug for melasma and was first reported in 1979 when Nijo Sadako tried to use it to treat a patient with chronic urticaria. This was an accidental finding but prompted studies of TA on melasma patients [33]. As a skin-lightening agent, TA has been used as a topical, intradermal microinjection, and oral agent [11]. Although TA has emerged as a potential treatment for melasma, it has not been approved by Food and Drug Administration of the United States for melasma and treatment remains controversial [10, 33, 34]. Consequently, in this study, we conducted a systematic review to evaluate the therapeutic effect of TA for treating melasma.

2. Materials and Methods

The protocol of this systematic review and meta-analysis was registered in advance with the PROSPERO international prospective register of systematic reviews (registration number CRD42018095168) and conforms to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement [35]. This study does not require an ethical review.

2.1. Database and Search Strategy. In this study, the PubMed (https://www.ncbi.nlm.nih.gov/pubmed), EMBASE (https://www.embase.com/), and the Cochrane Library (https://www.cochranelibrary.com/) databases were searched for original studies and the search was conducted on 26 April 2018. The following keywords and their combinations were used: “melasma”, “chloasma”, “tranexamic acid”, “antifibrinolytic agents”, and “trans-4-(Aminomethyl)cyclohexane-carboxylic acid”.

2.2. Inclusion and Exclusion Criteria. Two reviewers (LZ and XWW) independently qualified all studies, and if the evaluations did not yield a final decision, a third reviewer (WQT) was invited to make a decision. Qualified studies had to satisfy the following inclusion criteria: (1) original studies (randomized controlled trials (RCTs), cohort studies, and case-control studies) describing treatment for melasma with TA; (2) TA treatment either alone or in combination with other treatments; (3) studies reporting one of the melasma outcome measures such as the Melasma Area and Severity Index (MASI), the Melanin Index (MI), and Erythema Index (EI). Principal criteria for the exclusion of studies were as follows: (1) irrelevant topic, duplicate, review, and comment; (2) no appropriate or complete data; (3) studies not reporting melasma specific outcome measures.

2.3. Data Extraction. All data from the qualified studies were independently extracted by two reviewers (LZ and XWW). The following types of data were extracted: study characteristics (first author, publication year, countries/regions, and sample size of participants), pharmacotherapy intervention, administration methods, duration of follow-up, outcomes (MASI, MI, and EI), and adverse reaction. Any disagreement was resolved by discussion.

2.4. Quality Assessment. RCTs were evaluated by the Cochrane risk-of-bias tool [36]. And we adopted the risk-of-bias criteria suggested by Newcastle-Ottawa Scale for case-control studies and cohort studies (http://www.ohri.ca/). Two reviewers (LZ and XWW) independently assessed methodological quality of each study. Any disagreements were resolved by consensus or by consultation with a third review (WQT).

2.5. Statistical Analysis. The Review Manager Version 5.3 (the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark) and STATA Version 15.1 software (StataCorp, TX, USA) were used for data analysis. Our main indicators of treatment for melasma by TA were the difference in MASI, MI, and EI scores before and after the treatment and the difference in MASI score between a routine treatment and that with TA as an adjuvant. We analyzed the data using a random-effect model, and heterogeneity across pooled studies was tested using Cochrane Q via a Chi² test, quantifying with the I² statistic. And P < 0.5 and I² > 50% indicate a significant heterogeneity between studies. The continuous outcome data were expressed as standardized mean differences (SMD) and the 95% confidence intervals (CIs) were also calculated. Subgroup analyses were conducted in these studies by the TA administration (oral TA, topical TA, and TA injection). Egger test was carried out to investigate the publication bias of enrolled studies.

3. Result

3.1. Search Results. We used a flow chart to make the search process more detailed (Figure 1). A total of 139 articles in English were retrieved for this study from databases specified in Section 2.1. About 97 articles were excluded for duplication. After reviewing the title and abstract, 15 articles were excluded for reviews. Finally, the remaining 23 full-text articles were assessed for eligibility. Additional 2 articles were excluded for the lack of important outcomes. Eventually, 21 studies were incorporated into the information integration [11–30, 37].

3.2. Study Characteristics. The main characteristics of these included studies are shown in Table 1. The included studies were published between 2006 and 2018, which were comprised of 16 RCTs, 3 cohort studies, and 2 case-control studies. Among these 21 trials, 6 were conducted in Korea, 5 in Iran, 4 in India, 2 in China, 1 in Brazil, 1 in Nepal, 1 in Singapore, and 1 in USA. These studies involved a total of 1563 patients.
Table 1: The characteristics of included studies.

| Study (first author, year) | Country | Completed/Participants | Age, y | Delivery mode | TA treatment * | Primary outcome § | Side effects (patients) |
|----------------------------|---------|------------------------|--------|---------------|----------------|-------------------|------------------------|
| Shin 2013[11]              | Korea   | 44/48                  | 48 (28-56) | Oral | 750mg (Qd, 8W) + QS NY (2 rounds, 4W intervals) | mMASI | Heartburn (1); Nausea (1) |
| Budamakuntla 2013[12]      | India   | 52/60                  | (18-50) | Injection | MI: 8mg (Qm, 8W) MN: 2-4mg (Qm, 8W) | mMASI | Itching (4); Burning (3); Erythema (8) |
| Lajevardi 2016[13]         | Iran    | 88/100                 | (18-65) | Oral | 250mg (Tid, 12W) + Topical 4% HQ (Qn, 12W) | MASAI | Therapy-related complications (3); Abdominal pain (2) |
| Banihashemi 2015[14]       | Iran    | 23/30                  | (25-47) | Topical | 5% TA (Qn, 12W) | MASAI | None |
| Na 2012[15]                | Korea   | 22/25                  | (20-55) | Oral + Topical | Oral TA 250mg (Tid, 8W) + Topical 2% TA (Bid, 8W) | MI; EI | None |
| Kim 2016[16]               | Korea   | 23/23                  | (34-60) | Topical | Emulsion 2% TA (Bid, 12W) + Fabric mask 2% TA (Tiw, 12W) | mMASI | None |
| Lee 2006[17]               | Korea   | 85/100                 | 38 (29-46) | Injection | 0.2mg/cm² (Qw, 12W) | MASAI | Erythema (2); Burning (2); Hypopigmentation/Depigmentation (2); Oligomenorrhoea (1) |
| Padhi 2015[18]             | India   | 40/40                  | 36 (24-55) | Oral | 250mg (Bid, 8W) + Topical 4% HQ (Qd, 8W) | MSAI | Oligomenorrhoea (19); Belching (12); Abdominal cramps (9); Palpitation (1); Urticarial rash with angioedema (1) |
| Karn 2012[19]              | Nepal   | 260/260                | 30 (17-55) | Oral | 250mg (Bid, 12W) + Topical HQ | MASAI | None |
| Tan 2016[20]               | Singapore | 25/25                | 47 (32-63) | Oral | 250mg (Bid, 12W) | MASAI | None |
| Rosario 2017[21]           | USA     | 39/44                  | 44 (-) | Oral | 250mg (Bid, 12W) | mMASI | Moderate myalgias (1) |
| Cho 2013[22]               | Korea   | 51/51                  | 41 (-) | Oral | 500mg (Qd, 8W) + IPL + QS NY (3-4 rounds, 1-2W intervals) | mMASI | Transient headache (4) |
| Atefi 2017[23]             | Iran    | 60/60                  | 39 (-) | Topical | 5% TA (Bid, 12W) | MASAI | None |
| Sharma 2016[24]            | India   | 80/100                 | 37 (18-55) | Oral | Oral TA 250mg (Bid, 12W) + Injection 4mg (3 rounds, 4W intervals) | MASAI | Oral: Hypomenorrhoea (6); Epiagastric discomfort (2); Injection: Injection site pain and transient oedema (13) |
| Ebrahimi 2014[25]          | Iran    | 39/50                  | 40 (29-51) | Topical | 3% TA (Bid, 12W) | MASAI | Erythema, skin irritation, xerosis, and scaling (Total: 9) |
| Study (first author, year) | Country | Completed/Participants | Age, y  | Delivery mode | TA treatment* | Primary outcome§ | Side effects (patients) |
|---------------------------|---------|-----------------------|---------|---------------|--------------|------------------|------------------------|
| Chung 2015[26]            | Korea   | 13/15                 | 41† (-) | Topical       | 2% TA (12W) + IPL (4 rounds, 4W intervals) | mMASI | None |
| Thillaikkarasi 2017[27]   | India   | 48/60                 | 40‡ (-) | Oral Injection| Oral TA 250mg (Bid, 12W) TA Injection 4mg (3 rounds, 4W intervals) | MASI | Hypothyroidism (5); Irregular menstrual cycle (7 females); Depression and anxiety (38) |
| Saki 2017[28]             | Iran    | 31/37                 | 36† (25-49) | Injection | 3 rounds, 4W intervals | MI; EI | Unknown |
| Steiner 2009[29]          | Brazil  | 17/18                 | 41‡ (23-52) | Topical Injection | Topical 3% TA (Bid, 12W) TA Injection 0.2mg/cm² (Qw, 12W) | MASI | Side effects were minimal. |
| Lu 2017[30]               | China   | 81/84                 | 43† (23-58) | Topical | 2.5% TA (7h/d, 8W) | MASI | None |
| Xu 2017[31]               | China   | 28/30                 | 39‡ (20-50) | Topical | 0.5% TA (Qw, 12W) | MI; EI | None |

*TA: tranexamic acid, HQ: hydroquinone, Qd: once a day, Qn: once a night, Bid: twice a day, Tid: thrice a day, Qm: once a month, Qw: once a week, TIw: thrice a week, QSNY: low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet, MI: microinjection, MN: microneedling, IPL: intense pulsed light.

MASI: Melasma Area and Severity Index, mMASI: modified Melasma Area and Severity Index, MI: Melanin Index, EI: Erythema Index.

†Median age. ‡Mean age.
with melasma. All patients in these studies were adults, 80%-100% women. Melasma severity was evaluated by MASI, MI, and EI (12 studies were assessed with the original MASI score, 6 studies were assessed with the modified MASI score, 3 studies were assessed with the MI score, and 3 studies were assessed with EI score). TA was delivered orally, topically, and through physical methods in these articles. The oral groups patients received a daily dose of 500mg or 750mg [11, 13, 15, 18–22, 24, 27]. And the dose of injection TA ranged from 2-8mg to the entire affected area or was 0.2mg/cm² in affected area [12, 17, 24, 27–29]. In addition, the form of topical TA included liposome [14], emulsion/cream [16, 29], skin lotion [16, 25, 37], and cataplasm [30]. And 0.5%-5% TA was administrated to each patient in the topical group [14–16, 23, 25, 26, 29, 30, 37]. The mean treatment time was approximately 8 to 12 weeks.

3.3. Quality Assessment. The quality of the studies is evaluated respectively by the Cochrane risk-of-bias tool in Table 2 and Newcastle-Ottawa Scale in Tables 3 and 4. The quality of the studies evaluating TA treatment in melasma varied. However, only a few studies were assessed as having high quality.

3.4. Effects of Interventions

3.4.1. Comparison of MASI Score Change. MASI score reduction, defined as change in MASI score before and after treatment, was the primary outcome measure of 12 studies with TA treatment alone [12, 14, 16, 17, 20, 21, 23–25, 27, 29, 30]. Among these studies, 5 trials [12, 17, 24, 27, 29] with TA injection were pooled together using the random effects model (SMD, -1.673; 95% CI, -1.990 to -1.356; \( P < 0.0001; I^2 = 47.6\% \)). Six trials with topical TA were pooled together to be analyzed [14, 16, 23, 25, 29, 30], and the random effects model was applied (SMD, -1.850; 95% CI, -2.556 to -1.144; \( P < 0.0001; I^2 = 85.6\% \)). Furthermore, 4 pooled trials [20, 21, 24, 27] with oral TA were used by the random effects model (SMD, -1.866; 95% CI, -2.456 to -1.276; \( P < 0.0001; I^2 = 71.6\% \)). Overall, TA treatment alone induced a significant reduction of MASI score (SMD, -1.783; 95% CI, -2.076 to -1.490; \( P < 0.0001; I^2 = 73.2\% \)). There was high and statistically significant heterogeneity within TA treatment alone subgroups, as shown in the wide confidence intervals (Figure 2). However, there was no heterogeneity among 3 subgroups (\( I^2 = 0\% \)). MASI score change was also compared to the routine treatment of melasma combined with or without TA adjuvant treatment in 6 studies [11, 13, 18, 19, 22, 26]. Among these studies, routine treatment included low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) [11, 22], topical 4% hydroquinone [13, 18, 19], and intense pulsed light (IPL) [22, 26]. Oral TA was applied as an adjuvant treatment in 5 studies [11, 13, 18, 19, 22]. And topical TA was applied only in 1 study [26]. The results of the 5 pooled trials with oral TA adjuvant treatment using the random effects model (SMD, 0.629; 95% CI, 0.216 to 1.042; \( P = 0.003 \)) showed high heterogeneity (\( I^2 = 73.8\% \)), suggesting that MASI score reduction was greater...
Table 2: Risk-of-bias assessment of included randomized controlled trials*.

| Study (first author, year) | Adequate sequence generation | Allocation concealment | Blinding of participants | Blinding of assessment | Incomplete outcomes data addressed | Selective reporting | Free of other bias |
|----------------------------|------------------------------|------------------------|--------------------------|------------------------|-----------------------------------|--------------------|------------------|
| Atefi 2017                 | Low                          | Low                    | Low                      | Unclear                | Low                               | Unclear            | Unclear          |
| Banihashemi 2015           | Unclear                      | Unclear                | High                     | Unclear                | High                              | Unclear            | Unclear          |
| Budamakuntla 2013          | Unclear                      | Unclear                | Low                      | High                   | High                              | Unclear            | Unclear          |
| Chung 2015                 | Unclear                      | Unclear                | High                     | High                   | High                              | Unclear            | Unclear          |
| Ebrahimi 2014              | Unclear                      | Unclear                | Low                      | Unclear                | Low                               | Unclear            | Unclear          |
| Karn 2012                  | Low                          | Unclear                | High                     | High                   | Low                               | Unclear            | Unclear          |
| Lajevardi 2016             | Low                          | Low                    | High                     | Low                    | Low                               | Unclear            | Unclear          |
| Lu 2017                    | Low                          | Unclear                | High                     | High                   | Low                               | Unclear            | Unclear          |
| Padhi 2015                 | Unclear                      | High                   | Low                      | Low                    | Low                               | Unclear            | Unclear          |
| Rosario 2017               | Low                          | Low                    | High                     | Low                    | Low                               | Unclear            | Unclear          |
| Saki 2017                  | Unclear                      | Unclear                | High                     | High                   | High                              | Unclear            | Unclear          |
| Sharma 2016                | High                         | Unclear                | High                     | Low                    | Unclear                           | Unclear            | Unclear          |
| Shin 2013                  | Unclear                      | Unclear                | High                     | Low                    | Low                               | Unclear            | Unclear          |
| Steiner 2009               | Unclear                      | Unclear                | High                     | Low                    | Unclear                           | Unclear            | Unclear          |
| Thillaikkarasi 2017        | Low                          | High                   | High                     | Unclear                | Unclear                           | Unclear            | Unclear          |
| Xu 2017                    | Unclear                      | High                   | High                     | Low                    | Unclear                           | Unclear            | Unclear          |

* Risk of bias was assessed with use of the Cochrane risk-of-bias tool.

in the subgroup of TA adjuvant treatment. Additionally, topical TA adjuvant treatment was also found to reduce the MASI score (SMD, 0.618; 95% CI, -0.171 to 1.406), but the difference was not statistically significant ($P = 0.125$). Taken altogether, the heterogeneity was high within the TA adjuvant treatment subgroup ($I^2 = 67.5\%$) (Figure 3), but there was no heterogeneity between the 2 subgroups ($I^2 = 0\%$).

3.4.2. Comparison of MI Score Change. MI score change was defined as change in MI score before and after treatment. Three trials were pooled together [15, 28, 37] using the random effects model (SMD, -0.689; 95% CI, -1.217 to -0.160; $P = 0.011$; $I^2 = 62.7\%$), suggesting that TA treatment significantly decreased MI score (Figure 4).

3.4.3. Comparison of EI Score Change. Similarly, EI score change was also defined as change in EI score before and after treatment. Three trials were pooled together [15, 28, 37] using the random effects model (SMD, -0.677; 95% CI, -1.507 to 0.153; $P = 0.110$; $I^2 = 84.5\%$). There was no significant difference in EI score measured before and after TA treatment (Figure 5).

3.5. Side Effects. In the included 21 studies, 10 trials were related to the side effects (Table 1). The side effects of patients with melasma after oral TA application mainly showed gastrointestinal reaction such as heartburn, nausea, abdominal pain, and epigastric discomfort [11, 13, 19, 24]. And some patients showed oligomenorrhea, hypopigmentation, urticarial rash with angioedema, moderate myalgias, transient headache, anxiety, and depression [18, 21, 22]. Additionally, patients with topical TA treatment showed side effects such as skin irritation, xerosis, and scaling [25]. The patients with TA injection just showed transient oedema and injection site pain [24]. However, small number of erythema cases appeared in all oral, topical, and injectional TA subgroups [12, 18, 25].

3.6. Publication Bias. The included articles’ publication bias was evaluated through STATA 15.1 software. Because both of the indicators of MI and EI only had 3 articles, they did not meet the standard of the funnel map, which was without special significance. And we assessed the publication bias to the MASI score by using the Egger method. The results showed that the MASI score comparison showed no significant publication bias ($P = 0.760$) (Figure 6, Table 5).

4. Discussion

This meta-analysis of individual patient data from 1563 adults regardless of sex randomized in trials of single and adjuvant TA found a highly significant reduction in MASI and MI scores, but not in EI score. Subgroup analysis suggested benefit in oral, topical, and injectional TA alone and adjuvant oral TA; among whom there were highly significant reductions in MASI score. However, adjuvant topical TA did not show...
| Study (first author, year) | Representativeness of exposed cohort | Selection | Ascertainment of exposure | Demonstration that outcomes† | Comparability | Outcome | Adequacy of follow-up of cohorts | Score |
|---------------------------|-------------------------------------|-----------|---------------------------|-----------------------------|---------------|---------|--------------------------------|-------|
| Kim 2016                  | ⋆                                   | -         | ⋆                         | ⋆                           | ⋆             | ⋆       | ⋆                              | 7     |
| Lee 2006                  | ⋆                                   | -         | ⋆                         | ⋆                           | ⋆             | ⋆       | ⋆                              | 6     |
| Na 2012                   | ⋆                                   | -         | ⋆                         | ⋆                           | ⋆             | ⋆       | ⋆                              | 6     |

*The assessment was based on the Newcastle-Ottawa Scale. The full mark of total score is defined as 9; a score of >7 indicates a low risk of bias.
†A demonstration about the outcomes of interest was not present initially.
### Table 4: Assessment of the quality of case-control studies.

| Study (first author, year) | Definition adequate? | Representativeness of cases | Selection of controls | Definition of controls | Comparability† | Ascertainment of exposure | Exposure | Same method of ascertainment | Nonresponse rate | Score |
|---------------------------|----------------------|----------------------------|-----------------------|------------------------|----------------|---------------------------|----------|-----------------------------|-----------------|-------|
| Cho 2013                  | ✪                    | ✪                          | ✪                     | ✪                      | ✪              | ✪                         | ✪        | ✪                           | -               | 8     |
| Tan 2016                  | ✪                    | ✪                          | -                     | ✪                      | ✪              | ✪                         | ✪        | ✪                           | ✪               | 6     |

* The assessment was based on the Newcastle-Ottawa Scale. The full mark of total score is defined as 9; a score of >7 indicates a low risk of bias.
† Comparability of cases and controls on the bias of design or analysis.
Table 5: Egger’s test of publication bias.

| Outcome          | Std. Eff. | Coef.  | Std. Err. | t      | P > | [95% Conf. Interval] |
|------------------|-----------|--------|-----------|--------|-----|---------------------|
| MASI score       | Slope     | -1.974574 | 0.5844401 | -3.38  | 0.005 | -3.228074 to -0.7210746 |
|                  | Bias      | 0.6088802 | 1.955849  | 0.31   | 0.760 | -3.585999 to 4.803759  |

NOTE: Weights are from random effects analysis.

Overall (I-squared = 73.2%, p = 0.000)

Sharma (2016)
Lee (2006)
Sharma (1) (2016)
Thillaikkarasi (1) (2017)

Subtotal (I-squared = 47.6%, p = 0.090)

Banihashemi (2015)
Kim (2016)
Steiner (1) (2009)
Ebrahimi (2014)
Lu (2017)
Atefi (2017)

Subtotal (I-squared = 85.6%, p = 0.000)

Oral TA
Tan (2016)
Rosario (2017)
Sharma (2016)
Thillaikkarasi (2017)

Subtotal (I-squared = 71.6%, p = 0.014)

Overall (I-squared = 73.2%, p = 0.000)

SMD (95% CI) % Weight

-1.20 (-1.75, -0.65) 6.79
-1.24 (-1.79, -0.69) 6.78
-2.01 (-2.37, -1.66) 7.91
-1.71 (-2.77, -0.64) 4.08
-1.82 (-2.31, -1.33) 7.14
-1.98 (-2.67, -1.29) 5.97
-1.67 (-1.99, -1.36) 38.68
-3.14 (-3.96, -2.33) 5.27
-0.82 (-1.42, -0.21) 6.49
-0.55 (-1.55, 0.45) 4.37
-2.10 (-2.63, -1.58) 6.96
-1.68 (-2.18, -1.18) 7.08
-2.74 (-3.45, -2.03) 5.86
-1.85 (-2.56, -1.14) 36.04

Figure 2: Forest plot showing the comparisons of Melasma Area and Severity Index (MASI) score change between post- and pre-tranexamic acid (TA) treatment alone.

A recent meta-analysis published during the last few years assessed the effectiveness and safety of TA for melasma [40]. Compared with previous systematic review, 12 studies [11, 13–16, 21, 23, 24, 27, 28, 30, 37] of this review were newly included. And most of these articles are published in 2017 or 2018. Importantly, we conducted a subgroup analysis in different administrations of TA and publication bias analysis which was performed by Egger test. Moreover, besides MASI score,

melanocytic tyrosinase activity by blocking the interaction of melanocytes and keratinocytes through the inhibition of the plasminogen/plasmin system [32]. However, TA treatment for melasma remains controversial.

a significant difference in MASI score compared with the routine treatment because just one study was included [26].

TA was often applied to inhibit bleeding by its effects on blocking plasminogen activation and thus subsequently stopping fibrinolysis [31, 38]. Although the indications for TA did not include treatment of patients with melasma, the potential efficacy for melasma has been consistently reported since the 1980s. It is generally known that melasma is an acquired disorder of symmetrical hyperpigmentation. UV radiation induces the synthesis of PA by keratinocytes, which results in increased conversion of plasminogen to plasmin [39]. TA can suppress UV induced epidermal
| Study ID | SMD (95% CI) | Weight |
|----------|--------------|---------|
| Lajevardi (2016) | 0.79 (0.35, 1.22) | 19.36 |
| Shin (2013) | 0.28 (-0.32, 0.87) | 15.58 |
| Karn (2012) | 0.30 (0.06, 0.55) | 23.86 |
| Cho (2013) | 0.37 (-0.18, 0.93) | 16.47 |
| Subtotal (I-squared = 73.8%, p = 0.004) | 0.63 (0.22, 1.04) | 88.17 |

**Topical TA**

| Study ID | SMD (95% CI) | Weight |
|----------|--------------|---------|
| Chung (2015) | 0.62 (-0.17, 1.41) | 11.83 |
| Subtotal (I-squared = 73.8%, p = 0.004) | 0.62 (-0.17, 1.41) | 11.83 |

**Overall (I-squared = 67.5%, p = 0.009)**

| SMD (95% CI) | Weight |
|--------------|---------|
| 0.62 (0.26, 0.98) | 100.00 |

**NOTE:** Weights are from random effects analysis

**Figure 3:** Forest plot showing the comparisons of Melasma Area and Severity Index (MASI) score change between the routine treatment combined with or without tranexamic acid (TA) adjuvant treatment.

| Study ID | SMD (95% CI) | Weight |
|----------|--------------|---------|
| Na (2012) | -1.13 (-1.75, -0.52) | 30.78 |
| Xu (2017) | -0.21 (-0.73, 0.31) | 35.31 |
| Saki (2017) | -0.78 (-1.33, -0.24) | 33.91 |
| Overall (I-squared = 62.7%, p = 0.069) | -0.69 (-1.22, -0.16) | 100.00 |

**NOTE:** Weights are from random effects analysis

**Figure 4:** Forest plot showing the comparisons of Melanin Index (MI) score change between post- and pre-tranexamic acid (TA) treatment alone.
more indicators (MI and EI) for melasma were also detected in this systematic review. The MASI, an index devised to accurately quantify the severity of melasma and changes during therapy, was first used by Kimbrough-Green et al. [41]. Experts in melasma have used the MASI score as the predominant outcome measure for almost 20 years, suggesting that it has content validity as well [6, 8, 41, 42]. Although individual components are problematic, particularly assessment of homogeneity and chin, MASI score system is still the most commonly used outcome measure for melasma [43]. MI score is regarded as a parameter which is mainly influenced by the melanin content [44]. Compared with whole-face assessment of MASI score, MI and EI scores are measured in melasma area (lesional skin area) by reflectance instruments [15, 28, 31]. Besides, some trials included in this study did not use the MASI score because it is composed of scores of areas and severity of the whole face, so it cannot be used for split-face assessments [31].

In our study, we proved that TA is a safe and efficient medicine for melasma patients. Both single and adjuvant TA treatments showed a significant reduction of MASI and MI scores while incurring minimal side effects. However, the combined results of 3 trials [15, 28, 37] showed no significant difference in EI score with or without TA treatment. Because of design differentials, it cannot be confirmed that TA cannot induce EI reduction in melasma patients. It is known that plasmin plays an important role in angiogenesis, as it converts extracellular matrix-bound vascular endothelial growth factor into freely diffusible forms, whereas TA inhibits angiogenesis and also suppresses neovascularization induced by basic fibroblast growth factor [37]. More high-quality trials will be needed to provide strong evidence of the effect of TA for EI reduction.

The daily systemic doses of TA reported for the treatment of melasma have ranged from 500mg to 700mg, and the effective daily dose is much lower for menorrhagia and perioperative hemophilia patients [32, 39]. Nevertheless, given the potential for serious side effects with the use of oral TA, there has been interest in evaluating injection or topical TA for melasma [12, 14, 16, 17, 23, 25, 26, 28–30, 37]. Topical TA has been applied alone and in conjunction with intradermal injection, microneedling, fractionated CO2 laser, and so on to increase bioavailability [28, 37, 45]. However, the currently available data are limited by small sample sizes.
and the design of poor quality. Debate exists about whether topical water-soluble TA is transdermally absorbed by the lipid-soluble surface of the skin. In addition to bridging the knowledge gaps in our understanding of topical as an option for melasma patients, further studies on clinical efficacy and side effects comparisons among different administrations of TA should be carried out.

There are some limitations of this meta-analysis and system review which are as follows. Firstly, trials included in this meta-analysis had various follow-up times and different doses and used different forms of MASI score. Secondly, the quality of studies was low and assessment of the MASI score may be influenced by the subjective factors in the process. In addition, there was greater heterogeneity of MASI, MI, and EI in this systematic review which may be due to sample size and quality of studies. However, it is worth noting that high heterogeneity is more common in continuous variables [46].

We conducted a subgroup analysis in different TA modes of administration, and different degrees of reductions of intra-subgroup $I^2$ were observed. However, it is difficult to evaluate the heterogeneity in terms of individual differences. Despite the disadvantages mentioned above, this systematic review and meta-analysis provides preliminary evidence currently available on the application of TA for melasma patients.

5. Conclusion

According to the results of meta-analysis, TA is an effective and safe therapy for melasma patients. However, the findings are insufficient to make a firm conclusion due to the lack of studies with high methodological quality. More rigorously designed trials with larger sample size are needed to confirm the effectiveness and safety of TA for melasma.

Conflicts of Interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors’ Contributions

Lei Zhang and Wei-Qiang Tan designed the experiment. Lei Zhang and Xiao-Wei Wang extracted data. Wan-Yi Zhao, Qi-Ming Zhao, and Jie Gao performed all statistical analyses. Lei Zhang drafted the paper. All authors reviewed and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 81671918), the National Key Research Program of China (Grant No. 2016YFC1010004), and Zhejiang Grants Funded by Provincial Health and Family Planning Commission (Grant No. 2015EYB105).

References

[1] K. D. Werlinger, I. L. Guevara, C. M. González et al., “Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex [2],” JAMA Dermatology, vol. 143, no. 3, pp. 424–425, 2007.

[2] V. M. Sheth and A. G. Pandya, “Melasma: A comprehensive update: Part II,” Journal of the American Academy of Dermatology, vol. 65, no. 4, pp. 699–714, 2011.

[3] A.-Y. Lee, “Recent progress in melasma pathogenesis,” Pigment Cell & Melanoma Research, vol. 28, no. 6, pp. 648–660, 2015.

[4] A. Lee, “An updated review of melasma pathogenesis,” Dermatologica Sinica, vol. 32, no. 4, pp. 233–239, 2014.

[5] B. W. Lee, R. A. Schwartz, and C. K. Janniger, “Melasma, Gior nale italiano di dermatologia e venerologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, vol. 152, no. 1, pp. 36–45, 2017.

[6] R. Balkrishnan, A. J. McMichael, F. T. Camacho et al., “Development and validation of a health-related quality of life instrument for women with melasma,” British Journal of Dermatology, vol. 149, no. 3, pp. 572–577, 2003.

[7] T. J. Lieu and A. G. Pandya, “Melasma Quality of Life Measures,” Dermatologic Clinics, vol. 30, no. 2, pp. 269–280, 2012.

[8] A. R. Dominguez, R. Balkrishnan, A. R. Elzey, and A. G. Pandya, “Melasma in Latina patients: Cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language,” Journal of the American Academy of Dermatology, vol. 55, no. 1, pp. 59–66, 2006.

[9] F. M. Freitag, T. F. Cestari, L. R. Leopoldo, P. Paludo, and J. C. Boza, “Effect of melasma on quality of life in a sample of women living in southern Brazil,” Journal of the European Academy of Dermatology and Venereology, vol. 22, no. 6, pp. 655–662, 2008.

[10] M. Rodrigues and A. G. Pandya, “Melasma: Clinical diagnosis and management options,” Australasian Journal of Dermatology, vol. 56, no. 3, pp. 151–163, 2015.

[11] J. U. Shin, J. Park, S. H. Oh, and J. H. Lee, “Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: A randomized, prospective trial,” Dermatologic Surgery, vol. 39, no. 3, pp. 435–442, 2013.

[12] L. Budamakunta, E. Loganathan, D. Suresh et al., “A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma,” Journal of Cutaneous and Aesthetic Surgery, vol. 6, no. 3, p. 139, 2013.

[13] V. Lajevardi, A. Ghayouni, R. Abedini et al., “Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: A parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up,” Journal of Cosmetic Dermatology, vol. 16, no. 2, pp. 235–242, 2017.

[14] M. Banishahemi, N. Zabolinejad, M. R. Jaafari, M. Salehi, and A. Jabari, “Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma,” Journal of Cosmetic Dermatology, vol. 14, no. 3, pp. 174–177, 2015.

[15] J. I. Na, S. Y. Choi, S. H. Yang, H. R. Choi, H. Y. Kang, and K.-C. Park, “Effect of tranexamic acid on melasma: A clinical trial with histological evaluation,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 8, pp. 1035–1039, 2013.
[16] S. J. Kim, J.-Y. Park, T. Shibata, R. Fujiwara, and H. Y. Kang, “Efficacy and possible mechanisms of topical tranexamic acid in melasma,” *Clinical and Experimental Dermatology*, vol. 41, no. 5, pp. 480–485, 2016.

[17] J. H. Lee, J. G. Park, S. H. Lim et al., “Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial,” *Dermatologic Surgery*, vol. 32, no. 5, pp. 626–631, 2006.

[18] T. Padhi and S. Pradhan, “Oral tranexamic acid with flucinolone-based triple combination cream versus flucinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial,” *Indian Journal of Dermatology*, vol. 60, no. 5, p. 520, 2015.

[19] D. Karn, S. KC, A. Amatya, E. A. Razouria, and M. Timalsina, “Oral tranexamic acid for the treatment of melasma,” *Kathmandu University Medical Journal*, vol. 10, no. 40, pp. 40–43, 2014.

[20] A. W. M. Tan, P. Sen, S. H. Chua, and B. K. Goh, “Oral tranexamic acid lightens refractory melasma,” *Australasian Journal of Dermatology*, vol. 58, no. 3, pp. e105–e108, 2017.

[21] E. DelRosario, S. Florez-Pollack, L. Zapata et al., “Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma,” *Journal of the American Academy of Dermatology*, vol. 78, no. 2, pp. 363–369, 2018.

[22] H. H. Cho, M. Choi, S. Cho, and J. H. Lee, “Role of oral tranexamic acid in melasma patients treated with IPL and low fluence Q5 Nd:YAG laser,” *Journal of Dermatological Treatment*, vol. 24, no. 4, pp. 292–296, 2013.

[23] N. Atefi, B. Dalvand, M. Ghassemi, G. Mehran, and A. Heydarian, “Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma,” *Dermatology and Therapy*, vol. 7, no. 3, pp. 417–424, 2017.

[24] R. Sharma, V. K. Mahajan, K. S. Mehta, P. S. Chauhan, R. Rawat, and T. N. Shiny, “Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study,” *Clinical and Experimental Dermatology*, vol. 42, no. 7, pp. 728–734, 2017.

[25] B. Ebrahimi and F. F. Naeini, “Topical tranexamic acid as a promising treatment for melasma,” *Journal of Research in Medical Sciences*, vol. 19, no. 8, pp. 753–757, 2014.

[26] J. Y. Chung, J. H. Lee, and J. H. Lee, “Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study,” *Journal of Dermatological Treatment*, vol. 27, no. 4, pp. 373–377, 2016.

[27] T. A. “Comparative Clinical Study of Oral Tranexamic Acid and Topical Tranexamic Acid with Microneedling in the Management of Melasma,” *Journal of Medical Science And clinical Research*, vol. 5, no. 11, 2017.

[28] N. Saki, M. Darayesh, and A. Heiran, “Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial,” *Journal of Dermatological Treatment*, pp. 1–6, 2017.

[29] D. Steiner, C. Feola, N. Bialeski et al., “Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma,” *tranexamic acid in treatment of melasma*, vol. 1, p. 174, 2009.

[30] J. Lu, L. Yang, P. Xu, F. Bian, and H. Zhang, “Whitening Efficacy of Tranexamic Acid Cataplasm on Melasma in Chinese Women,” *Integrative Medicine International*, pp. 154–160.

[31] I. Roberts, “Tranexamic acid in trauma: how should we use it?” *Journal of Thrombosis and Haemostasis*, vol. 13, pp. S195–S199, 2015.

[32] T. W. Tse and E. Hui, “Tranexamic acid: An important adjuvant in the treatment of melasma,” *Journal of Cosmetic Dermatology*, vol. 12, no. 1, pp. 57–66, 2013.

[33] H. R. Bala, S. Lee, C. Wong, A. Pandya, and M. Rodrigues, “Oral Tranexamic Acid for the Treatment of Melasma,” *Dermatologic Surgery*, vol. 44, no. 6, pp. 814–825, 2018.

[34] E. H. Kim, Y. C. Kim, E.-S. Lee, and H. Y. Kang, “The vascular characteristics of melasma,” *Journal of Dermatological Science*, vol. 46, no. 2, pp. 111–116, 2007.

[35] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation,” *British Medical Journal*, vol. 349, Article ID g7647, 2015.

[36] J. P. T. Higgins, D. G. Altman, P. C. Gettsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” *British Medical Journal*, vol. 343, no. 7829, Article ID d5928, 2011.

[37] Y. Xu, R. Ma, J. Juliandri et al., “Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma,” *Medicine (United States)*, vol. 96, no. 19, Article ID e6897, 2017.

[38] N. Bagherani, “The efficacy of tranexamic acid in the treatment of melasma,” *Dermatologic Therapy*, vol. 28, no. 4, p. 265, 2015.

[39] S. L. Sheu, “Treatment of melasma using tranexamic acid: What’s known and what’s next,” *Cutis: Cutaneous Medicine for the Practitioner*, vol. 101, no. 2, pp. E7–E8, 2018.

[40] H. J. Kim, S. H. Moon, S. H. Cho, J. D. Lee, and H. S. Kim, “Efficacy and safety of tranexamic acid in melasma: A meta-analysis and systematic review,” *Acta Dermato-Venereologica*, vol. 97, no. 7, pp. 776–781, 2017.

[41] C. K. Kimbrough Green, C. E. M. Griffiths, L. J. Finkel et al., “Topical Retinoic Acid (Tretinoin) for Melasma in Black Patients: A Vehicle-Controlled Clinical Trial,” *JAMA Dermatology*, vol. 130, no. 6, pp. 727–733, 1994.

[42] R. Balkrishnan, A. P. Kelly, A. McMichael, and H. Torok, “Improved quality of life with effective treatment of facial melasma: the pigment trial,” *Journal of drugs in dermatology: JDD*, vol. 3, no. 4, pp. 377–381, 2004.

[43] A. G. Pandya, L. S. Hyman, R. Bhore et al., “Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method,” *Journal of the American Academy of Dermatology*, vol. 64, no. 1, pp. 78–e2, 2011.

[44] H. Takiwaki, L. Overgaard, and J. Serup, “Comparison of narrow-band reflectance spectrophotometric and tristimulus colorimetric measurements of skin color: Twenty-three anatomical sites evaluated by the dermaspectrometer® and the chroma meter CR-200®,” *Skin Pharmacology and Physiology*, vol. 7, no. 4, pp. 217–225, 1994.

[45] C.-Y. Hsiao, H.-C. Sung, S. Hu, and C.-H. Huang, “Fractional CO2 laser treatment to enhance skin permeation of tranexamic acid with minimal skin disruption,” *Dermatology*, vol. 230, no. 3, pp. 269–275, 2015.

[46] A. C. Alba, P. E. Alexander, J. Chang, J. Macisaac, S. Defry, and G. H. Guyatt, “High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes,” *Journal of Clinical Epidemiology*, vol. 70, pp. 129–135, 2016.